Research Article

Oral Candida colonization in HIV-infected patients: Species and antifungal susceptibility in Tripoli/Libya

Ellabib M*, Mohamed H, Mokthar E, Ellabib M, El Magrahi H and Eshwika A

Published: 03 August, 2018 | Volume 1 - Issue 1 | Pages: 001-008

Introduction: Candidiasis is more frequent in human immunodeficiency virus (HIV)-infected patients and knowledge about the distribution and antifungal susceptibility of oral Candida species is important for effective management of candidiasis.

Material and Methods: An oral rinses sample collected from hundred HIV-infected patients with and without clinical evidence of oral candidiasis in this study at the Infectious Department/Tripoli Medical Center, Libya. Species identified by standard phenotypic and conventional methods and in vitro susceptibility testing of the yeast isolates to antifungals were performed using the Disc diffusion method protocol as recommended by the Clinical Laboratory Scientific Institute.

Results: Oral Candida colonization is detected in all patients with and without clinical syndromes, and Candida albicans were accounted for (74%), C. dubliniensis (11%) and C. glabrata (6%). A high proportion of Candida species (42%) showed decreased susceptibility to fluconazole. Among C., albicans more than 30% of isolate were resistant to most new azole antifungal including fluconazole, itraconazole, posoconazole and voriconazole.

Conclusions: A significant number of oral Candida species particular Candida albicans exhibiting decreased susceptibility to fluconazole were isolated from colonized HIV-infected individual, given the high incidence and severity of fungal infections in HIV-infected individuals. The results of this study reinforce the importance of antifungal susceptibility testing, which contributes to the therapeutic strategies and highlights the need for continuous surveillance of Candida colonization in this population.

Read Full Article HTML DOI: 10.29328/journal.ijcmbt.1001001 Cite this Article Read Full Article PDF


Candida; HIV; Azole resistance


  1. William JD, Timothy BG. Andrews' diseases of the skin: Clinical dermatology. Saunders Elsevier. 2006; 45.
  2. Crispian S. Oral and maxillofacial medicine: The basis of diagnosis and treatment (2nd ed). Edinburgh: Churchill Livingstone. 2008; 191-199.
  3. Fidel PL. Candida-host interactions in HIV disease: Relationships in oropharyngeal candidiasis. Adv Dent Res. 2006; 19: 80-84. Ref.: https://tinyurl.com/ybo4n8mn
  4. Mousavi SAA, Salari S, Rezaie S, Nejad NS, Hadizadeh S, et al. Identification of Candida species isolated from oral colonization in Iranian HIV-positive patients, by PCR-RFLP method. Jundishapur J Microbiol. 2012; 5: 336-340. Ref.: https://tinyurl.com/ya6sa46j
  5. Wabe NT, Hussein J, Suleman S, Abdella K. In vitro antifungal susceptibility of Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus in Ethiopia. J Exper and Integra Med. 2011; 1: 265-271. Ref.: https://tinyurl.com/yak5a2w4
  6. Khan AP, Malik A, Khan SH. Profile of candidiasis in HIV infected patients. Ira J of Microiol. 2012; 4: 204-209. Ref.: https://tinyurl.com/ycpztjby
  7. M Vajpayee, S Kanswal, P Seth, N Wig. Spectrum of Opportunistic Infections and Profile of CD4+Counts among AIDS Patients in North India. Infect. 2003; 31: 336-340. Ref.: https://tinyurl.com/ydxly745
  8. Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal colonization of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis. 1997; 25: 843-846. Ref.: https://tinyurl.com/y7omeuku
  9. Michelet C, Arvieux C, François C, Besnier JM, Rogez JP, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS. 1998; 12: 1815-1822. Ref.: https://tinyurl.com/ybw86yxp
  10. Tooyama H, Matsumoto T, Hayashi K, Kurashina K, Kurita H, et al. Candida concentrations determined following concentrated oral rinse culture reflect clinical oral signs. BMC Oral Health. 2015; 15: 150. Ref.: https://tinyurl.com/ybdpow64
  11. Jan A, Bashir G, Fomda BA, Khangsar DA, Manzoor M, et al. Hypertonic xylose agar medium: A novel medium for differentiation of Candida dubliniensis from Candida albicans. Indian J Med Microbiol. 2018; 35: 518-521. Ref.: https://tinyurl.com/y79ajhrq
  12. Khan ZU, Ahmad S, Mokaddas E, Chandy R. Simplified sunflower (Helianthus annuus) seed agar for differentiation of Candida dubliniensis from Candida albicans. Clin Microbiol Infect. 2004; 10: 590-592. Ref.: https://tinyurl.com/y75v62ww
  13. Clinical and Laboratory Standards Institute (CLSI). Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline-2nd ed. CLSI document M44-A2. Wayne. PA: CLSI. 2009.
  14. Clinical and Laboratory Standards Institute (CLSI). Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts, Third International Supplement CLSI document-M44-S3. Wayne. PA: CLSI. 2009.
  15. De Resende MA, de Sousa LV, de Oliveira RC, Koga-Ito CY, Lyon JP. Prevalence and Antifungal Susceptibility of Yeasts Obtained from the Oral Cavity of Elderly Individuals. Mycopathologia. 2006; 162: 39-44. Ref.: https://tinyurl.com/y9exh4v8
  16. Wabale V, Kagal A, Bharadwaj R. Characterization of Candida spp. from oral thrush in human immunodeficiency virus (HIV) seropositive and seronegative patients. Bombay Hospital J. 2008; 50: 212-217. Ref.: https://tinyurl.com/ya9j3esx
  17. Baradkar VP, Kumar S. Species identification of Candida isolates obtained from oral lesions of HIV infected patients. Indian J Dermatol. 2009; 54: 385-386. Ref.: https://tinyurl.com/y9vrzx2s
  18. Lattif AA, Uma B, Rajendra P, Biswas A, Wig N, et al. Susceptibility pattern and molecular type of speciesspecific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients. J Clin Microbiol. 2004; 42: 1260-1262. Ref.: https://tinyurl.com/ycx525bg
  19. Chunchanur SK, Nadgir SD, Halesh LH, Patil BS, Kausar Y, et al. Detection and antifungal susceptibility testing of oral Candida dubliniensis from human immunodeficiency virus-infected patients. Indian J Pathol Microbiol. 2009; 52: 501-504. Ref.: https://tinyurl.com/y9vco8s3
  20. Campisi G, Pizzo G, Milici M, Mancuso S, Margiotta V. Candidal colonization in the oral cavity of human immunodeficiency virus-infected subjects. Oral Surg Oral Med Oral Path Oral Radiol Oral Endod. 2002; 93: 281-286. Ref.: https://tinyurl.com/y8ntoyka
  21. Ellabib MS, ElJariny IA. In vitro activity of 6 antifungal agents on candida species isolated as causative agents from vaginal and other clinical specimens. Saudi Med J. 2001; 22: 860-863. Ref.: https://tinyurl.com/y9e5l9l4
  22. Krema ZA, Trfas EEM, Ellabib MS, Cogliati M. Oral colonization of candidiasis in patients with oral dental diseases: predisposing factors, species and their antifungal susceptibility patterns. Journal of Bacteriology & Mycology: Open Access. 2018; 6: 223-227.
  23. Arora U, Jagdev M, Jindal N. Immunosuppression level in HIV-positive patients with oropharyngeal Candidiasis. Indian J Med Microbiol. 2009; 27: 174-175. Ref.: https://tinyurl.com/yaxz8yom
  24. Costa CR, de Lemos JA, Passos XS, de Arau´jo CR, Cohen AJ, et al. Species distribution and antifungal susceptibility profile of oral Candida isolates from HIV-infected patients in the antiretroviral therapy era. Mycopathologia. 2006; 162: 45-50. Ref.: https://tinyurl.com/y76wryqg
  25. EYESON JD, TENANT-FLOWERS M, COOPER DJ, NW Johnson, KAAS Warnakulasuriya. Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London. J. oral Path. Med. 2002; 31: 169-174. Ref.: https://tinyurl.com/y855q52x
  26. Staszewski S1, Loveday C, Picazo JJ, Dellarnonica P, Skinhøj P, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA. 1996; 276: 111-117. Ref.: https://tinyurl.com/ycnf6haw
  27. Nicolatou-galitis O, Velegraki A, Paikos S, Economopoulou P, Stefaniotis T, et al. Effect of pi-haart on the prevalence of oral lesions in HIV-I infected patients. A Greek study. Oral Dis. 2004; 10: 145-150. Ref.: https://tinyurl.com/y8mlnu29
  28. Gugnani HC, Becker K, Fegeler W, Basu S, Chattopadhya D, et al. Oropharyngeal colonization of Candida species in HIV-infected patients in India. Mycoses. 2003; 46: 299-306. Ref.: https://tinyurl.com/y745fuqs
  29. Yang YL, Lo HJ, Hung CC, Li Y. Effect of prolonged HAART on oral colonization with Candida and candidiasis. BMC Infect Dis. 2006; 6: 8. Ref.: https://tinyurl.com/yc6622f8
  30. Sanchez-Vargas LO, Ortiz-Lopez NG, Villar M, Moragues MD, Aguirre JM, et al. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol. 2005; 22: 83-92. Ref.: https://tinyurl.com/y92stslu
  31. Vijeta Maurya, Ashutosh Srivastava, Jyoti Mishra, Rajni Gaind, Rungmei SK Marak, et al. Oropharyngeal candidiasis and Candida colonization in HIV positive patients in northern India. J Infect Dev Ctries. 2013; 7: 608-613. Ref.: https://tinyurl.com/ycy4nunm
  32. Sangeorzan JA, Bradley SF, He X, Lidija Zarins T, George Ridenour L, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 1994; 97: 339-346. Ref.: https://tinyurl.com/y8f3vqt3
  33. Sánchez-Vargas LO, Ortiz-López NG, Villar M, María Dolores Moragues, José Manuel Aguirre, et al. Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico. J Clin Microbiol. 2005; 43: 4159-4162. Ref.: https://tinyurl.com/yajt6aw9
  34. Thomas Campbell B, Laura Smeaton M, Kumarasamy N, Timothy Flanigan, Karin Klingman L, et al. Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings. PLOS Med. 2012; 9: e1001290. Ref.: https://tinyurl.com/ycty3qrh

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?